MPLT MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. (MPLT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 19% planned / 81% discretionary
Largest single sale: $1.6M.
Where they traded
Last open-market purchase: August 14, 2026 , by Catalyst4, Inc. .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Catalyst4, Inc. | 10% Owner | Buy | 4,400,000 | $11.38 | $50.1M | 25,306,689 | |
| Lillie James Woodruff | Chief Scientific Officer | Sell 10b5-1 | 22,082 | $12.54 | $276.9K | 202,380 −9.8% of holding | |
| Catalyst4, Inc. | 10% Owner | Buy | 1,000,000 | $13.00 | $13.0M | 20,906,689 | |
| Catalyst4, Inc. | 10% Owner | Buy | 3,000 | $12.63 | $37.9K | 19,906,689 | |
| Catalyst4, Inc. 2 fills | 10% Owner | Buy | 206,225 | $11.04 | $2.3M | 19,903,689 | |
| Cox Troy | Director | Buy | 15,620 | $9.52 | $148.7K | 15,620 | |
| GILLIS JONATHAN 3 fills | CAO and Interim CFO | Sell 10b5-1 | 18,469 | $37.60 | $694.5K | 162,109 −10.2% of holding | |
| Kreitzer Anatol 3 fills | Chief Discovery Officer | Sell 10b5-1 | 17,173 | $37.60 | $645.7K | 189,246 −8.3% of holding | |
| Kroeger Christopher A. | Chief Executive Officer | Sell | 16,779 | $37.90 | $635.9K | 1,246,455 −1.3% of holding | |
| Foff Erin Pennock | Chief Medical Officer | Sell | 3,656 | $37.90 | $138.6K | 298,901 −1.2% of holding | |
| Lillie James Woodruff | Chief Scientific Officer | Sell | 2,077 | $37.90 | $78.7K | 224,462 −0.9% of holding | |
| Hanson Kristopher | General Counsel | Sell | 1,130 | $37.90 | $42.8K | 145,823 −0.8% of holding | |
| Kroeger Christopher A. 3 fills | Chief Executive Officer | Sell | 69,082 | $36.79 | $2.5M | 1,291,417 −5.1% of holding | |
| Foff Erin Pennock 3 fills | Chief Medical Officer | Sell | 15,047 | $36.77 | $553.3K | 308,441 −4.7% of holding | |
| Kreitzer Anatol 2 fills | Chief Discovery Officer | Sell | 9,056 | $36.80 | $333.2K | 193,671 −4.5% of holding | |
| Lillie James Woodruff 3 fills | Chief Scientific Officer | Sell | 8,547 | $36.79 | $314.4K | 230,077 −3.6% of holding | |
| GILLIS JONATHAN 2 fills | CAO and Interim CFO | Sell | 8,455 | $36.80 | $311.1K | 164,185 −4.9% of holding | |
| Hanson Kristopher 3 fills | General Counsel | Sell | 8,118 | $36.78 | $298.6K | 150,295 −5.1% of holding | |
| Kroeger Christopher A. 3 fills | Chief Executive Officer | Sell | 61,778 | $36.69 | $2.3M | 1,375,144 −4.3% of holding | |
| Foff Erin Pennock 2 fills | Chief Medical Officer | Sell 10b5-1 | 15,000 | $36.62 | $549.3K | 338,904 −4.2% of holding | |
| Foff Erin Pennock 3 fills | Chief Medical Officer | Sell | 13,455 | $36.66 | $493.3K | 326,594 −4% of holding | |
| GILLIS JONATHAN 2 fills | CAO and Interim CFO | Sell | 10,055 | $36.51 | $367.1K | 175,863 −5.4% of holding | |
| Kreitzer Anatol 2 fills | Chief Discovery Officer | Sell | 10,055 | $36.49 | $366.9K | 205,645 −4.7% of holding | |
| Lillie James Woodruff 3 fills | Chief Scientific Officer | Sell | 7,643 | $36.70 | $280.5K | 240,491 −3.1% of holding | |
| Hanson Kristopher 3 fills | General Counsel | Sell | 7,260 | $36.70 | $266.4K | 160,184 −4.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.